Untapping host-targeting cross-protective efficacy of anticoagulants against SARS-CoV-2

Autor: Kambez H. Benam, Brian F. Niemeyer
Rok vydání: 2021
Předmět:
Drug repurposing
Host-targeting therapies
MSC
mesenchymal stem cell
medicine.disease_cause
TTSP
type II transmembrane serine protease
Mpro
virally encoded main protease of SARS-CoV-2
Pandemic
Nafamostat mesylate
Pharmacology (medical)
Coronavirus
COVID-19
coronavirus disease 2019
Drug discovery
Anticoagulant
MERS-CoV
Middle East respiratory syndrome coronavirus
IL1B
interleukin 1B
HIV
human immunodeficiency virus
Drug repositioning
Nrf2
nuclear factor erythroid 2 p45-related factor 2
VSV
vesicular stomatitis virus
medicine.drug_class
IL6
interleukin 6
SARS-CoV
severe acute respiratory syndrome coronavirus
ACE2
angiotensin-converting enzyme 2
Antiviral Agents
SARS-CoV-2
severe acute respiratory syndrome coronavirus 2
Virus
Article
RdRp
RNA dependent RNA polymerase
medicine
Humans
Antiviral
Pandemics
Pharmacology
Ang II
angiotensin II
business.industry
SARS-CoV-2
AT1
angiotensin II type 1 receptor
Virus Activation
Anticoagulants
medicine.disease
COVID-19 Drug Treatment
Pneumonia
PD-L1
programmed death-ligand 1
FasL
Fas ligand
COPD
chronic obstructive pulmonary disease
Immunology
Anti-inflammatory
business
CoV
coronaviruses
Zdroj: Pharmacology & Therapeutics
ISSN: 1879-016X
Popis: Responding quickly to emerging respiratory viruses, such as SARS-CoV-2 the causative agent of coronavirus disease 2019 (COVID-19) pandemic, is essential to stop uncontrolled spread of these pathogens and mitigate their socio-economic impact globally. This can be achieved through drug repurposing, which tackles inherent time- and resource-consuming processes associated with conventional drug discovery and development. In this review, we examine key preclinical and clinical therapeutic and prophylactic approaches that have been applied for treatment of SARS-CoV-2 infection. We break these strategies down into virus- versus host-targeting and discuss their reported efficacy, advantages, and disadvantages. Importantly, we highlight emerging evidence on application of host serine protease-inhibiting anticoagulants, such as nafamostat mesylate, as a potentially powerful therapy to inhibit virus activation and offer cross-protection against multiple strains of coronavirus, lower inflammatory response independent of its antiviral effect, and modulate clotting problems seen in COVID-19 pneumonia.
Databáze: OpenAIRE
Externí odkaz: